![\"\"](\"https:\/\/www.kachi.com.br\/wp-content\/uploads\/2026\/05\/ENGLISH-4S-MKT-by-ChatGPT.png\")
<\/p>\n<\/p>\n
In practice, the challenge in pharmaceutical marketing is not just to build awareness. It is to help physicians move confidently<\/strong> from content exposure to the adoption of new evidence or therapeutic options in clinical practice<\/strong>.<\/p>\n <\/p>\n That journey has become more complex. Medical education has never been so abundant \u2014 or so competitive. The problem today is no longer a lack of information. It is overload, fragmentation, and increasing competition for qualified attention.<\/p>\n <\/p>\n As the volume of information has exploded and channels have multiplied, access to healthcare professionals has become more selective and constrained. In the U.S., access to HCPs dropped from 60% in 2022 to 45% in 2024, and half of accessible professionals now engage with three or fewer companies.1<\/sup> At the same time, expectations are rising for interactions that are more relevant, better integrated, and genuinely useful<\/strong>.<\/p>\n <\/p>\n In this environment, the 4S framework of digital behavior <\/strong>offers a valuable lens for rethinking omnichannel strategy in Pharma<\/strong>: Streaming, Scrolling, Search, and Shopping.2,3<\/sup> In the medical context, however, the last \u201cS\u201d requires a more nuanced interpretation. More than \u201cpurchase,\u201d it represents clinical selection and informed adoption \u2014 in other words, the moment when knowledge becomes decision.<\/p>\n <\/p>\n This framework is especially useful for pharma marketing leaders because it helps answer a critical question:<\/p>\n <\/p>\n How do you turn content exposure into scientific trust \u2014 and scientific trust into clinical decision-making and prescribing behavior?<\/strong><\/p>\n <\/p>\n <\/p>\n <\/p>\n In the medical world, streaming goes beyond video. It refers to the continuous, flexible, and recurring consumption of scientific content in formats that fit fragmented schedules.<\/p>\n <\/p>\n This includes:<\/p>\n <\/p>\n From a pharma marketing standpoint, the value of streaming lies in three key areas:<\/p>\n <\/p>\n This matters because physicians and other HCPs continue to signal preference for hybrid and virtual educational formats \u2014 as long as the content is relevant, available on demand, and respectful of their time<\/strong>.4<\/sup><\/p>\n <\/p>\n Strategic implication for Big Pharma:<\/strong><\/p>\n Streaming should not be treated as a webinar archive. It must function as an editorial architecture<\/strong>.\u00a0 The real question is not, \u201cDo we have content?\u201d but rather, \u201cDo we have a content system that supports the HCP\u2019s clinical journey?\u201d<\/p>\n <\/p>\n The differentiator lies in delivering a planned sequence of content that supports different levels of depth, specialties, and points along the physician journey. In other words, the challenge is not simply to provide content. It is to provide high-value content, in a format aligned with the physician\u2019s routine and within an ethical, compliant communications framework.<\/p>\n <\/p>\n <\/p>\n <\/p>\n Scrolling is the stage of passive \u2014 or semi-passive \u2014 discovery. The physician is not necessarily looking for that specific content, but encounters it because it appears in a feed, an app, a physician group, a scientific portal, or a well-planned remote interaction.<\/p>\n <\/p>\n This includes:<\/p>\n <\/p>\n For pharmaceutical marketers, this stage is decisive because it shapes what will be remembered later. In crowded categories, many brands compete for the same mental real estate. The content that wins is not the one that appears most often \u2014 it is the one that appears with greater context, clarity, and usefulness<\/strong>.<\/p>\n <\/p>\n But there is a critical point here: in Pharma, scrolling without governance is risk. Feed logic must coexist with regulatory logic.<\/p>\n <\/p>\n In the U.S., the FDA, through the Office of Prescription Drug Promotion (OPDP), requires promotional communications to be truthful, balanced, and accurately communicated.7<\/sup><\/p>\n <\/p>\n Strategic implication for Big Pharma:<\/strong><\/p>\n Scrolling content must be built with dual capability \u2014 creative and medical-regulatory<\/strong>. In other words, it must be engaging without sacrificing accuracy, and concise without trivializing the evidence.<\/p>\n <\/p>\n That is highly relevant to this audience. It means that scientific scrolling content can \u2014 and should \u2014 be planned as a brand asset, as long as there is transparency, appropriate audience segmentation, and a clear distinction between promotional, educational, and scientific content.<\/p>\n <\/p>\n <\/p>\n <\/p>\n In the search phase, the logic changes. Physicians leave passive mode and enter problem-solving mode.<\/p>\n <\/p>\n Now there is a concrete question:<\/p>\n <\/p>\n At this stage, the physician turns to:<\/p>\n <\/p>\n From a pharma marketing perspective, search is a moment of truth. If the brand has performed well in streaming and scrolling, it has earned attention. But search is where it must sustain credibility<\/strong>. Healthcare professionals do not want just an attractive message; they want content that answers their real question with depth, clarity, and scientific grounding<\/strong>.<\/p>\n <\/p>\n This is where many strategies fail. Companies invest heavily in awareness, but deliver a poor experience when the HCP decides to go deeper: broken links, poorly curated literature, hard-to-find assets, summaries without context, overly promotional language, or a lack of clinically useful data.<\/p>\n <\/p>\n Strategic implication for Big Pharma:<\/strong><\/p>\n Search requires much tighter integration between marketing, medical, digital, and compliance. The right asset must exist, be approved, be discoverable, and answer the physician\u2019s real question \u2014 not simply support the brand\u2019s preferred narrative.<\/p>\n <\/p>\n For pharma marketing leaders, the lesson is clear: there is no strong search experience without a strong scientific foundation<\/strong>. And there is no strong scientific foundation without curation, appropriate language, compliance, and robust content architecture.<\/p>\n <\/p>\n <\/p>\n <\/p>\n In traditional marketing, shopping means purchase. In pharmaceutical marketing, that analogy is too limited. What happens here is more sophisticated: the physician evaluates whether new evidence deserves a place in practice<\/strong>.<\/p>\n <\/p>\n That is why, in the pharma context, it makes more sense to interpret the fourth \u201cS\u201d as Selection or Clinical Selection.<\/p>\n <\/p>\n This moment may involve:<\/p>\n <\/p>\n The decision rarely comes from a single channel. It is built through the cumulative effect of multiple experiences:<\/p>\n <\/p>\n In other words, there was enough trust to turn information into action<\/strong>.<\/p>\n <\/p>\n This reasoning also helps reposition the role of promotion. In pharmaceutical marketing, promotion should not be seen as mere commercial exposure. It remains relevant when it helps build:<\/p>\n <\/p>\n That is exactly why connected models integrating sales, marketing, and medical have become so important. Veeva shows that, despite reduced access, companies operating in a more connected way across these functions create more relevant and trusted relationships with HCPs, respond faster to HCP needs, and improve treatment adoption. The report also indicates that pre-launch education led by MSLs in partnership with KOLs can drive a 1.5x increase in adoption during the first six months post-launch.1<\/sup><\/p>\n <\/p>\n Strategic implication for Big Pharma:<\/strong><\/p>\n The goal of omnichannel is not to multiply touchpoints. It is to design a coherent progression from exposure to discovery, from discovery to deeper understanding, and from understanding to adoption<\/strong>.<\/p>\n <\/p>\n What This Changes in Marketing Planning<\/strong><\/p>\n <\/p>\n Viewing medical education through the lens of the 4Ss helps organize brand planning more intelligently<\/strong>.<\/p>\n <\/p>\n It makes no sense to treat webinars, social media, remote visits, scientific portals, email, and field force interactions as isolated tactics. Each one plays a role at a predominant stage of the physician journey.<\/p>\n <\/p>\n Physicians do not reward precision alone. They reward applied relevance. A scientifically flawless asset that is not actionable will lose to another that better addresses the physician\u2019s day-to-day clinical question.<\/p>\n That is why marketing and medical must work in close alignment. Once search begins, the HCP expects depth, comparability, and clarity. Without real integration between these functions, the journey breaks down.<\/p>\n <\/p>\n As access becomes more selective, insisting on volume can worsen the customer experience. The market increasingly rewards timing, personalization, and usefulness<\/strong> over repetition.<\/p>\n <\/p>\n In regulated markets, being present across multiple channels without a strong editorial and regulatory logic increases complexity and risk. Competitive advantage comes from orchestration, not from multiplying formats.<\/p>\n <\/p>\n The best-performing brands in this environment are precisely those that manage to be creative within regulatory discipline, not in spite of it.<\/p>\n <\/p>\n <\/p>\n Final Reflections<\/strong><\/p>\n <\/p>\n The medical education journey is not linear. A physician may discover a topic through scrolling, deepen understanding through search, later watch an educational session via streaming, and only then revise clinical practice. Still, thinking about that journey through the 4Ss helps answer a central question for Big Pharma marketing:<\/p>\n <\/p>\n How can brands build scientific experiences that are simultaneously relevant and useful to physicians, effective for the brand, and robust from a regulatory standpoint?<\/strong><\/p>\n <\/p>\n In complex markets, with multiple brands, highly competitive categories, and intense regulatory scrutiny, competitive advantage does not come simply from the volume of content produced. It comes from the ability to orchestrate science, context, creativity, and governance.<\/p>\n <\/p>\n That is exactly where scientific communication stops being a tactical deliverable and becomes a strategic brand lever.<\/p>\n <\/p>\n In the end, the difference between a brand that merely communicates and one that truly influences clinical decision-making does not lie in content volume. It lies in the ability to integrate science, context, creativity, and ethics<\/strong> into one coherent journey.<\/p>\n <\/p>\n At KACHI<\/strong>, we turn scientific evidence into content journeys that help pharmaceutical brands build relevance, trust, and clinical adoption with creativity, rigor, and compliance<\/strong>. If your brand needs a smarter strategy to connect science, channels, and medical decision-making, talk to KACHI.<\/p>\n <\/p>\n How to cite this article: KACHI Ci\u00eancia e Comunica\u00e7\u00e3o. The 4S Framework of Medical Education: How to Turn Scientific Content into Clinical Decision-Making and Prescribing Behavior. KACHI Comunica\u00e7\u00e3o Cient\u00edfica e Marketing Farmac\u00eautico [Internet]. 2026, Mar 17. Available from: https:\/\/kachi.com.br\/en\/article-4s-medical-education-scientific-content-prescribing<\/em><\/p>\n <\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":" In practice, the challenge in pharmaceutical marketing is not just to build awareness. It is to help physicians move confidently from content exposure to the adoption of new evidence or therapeutic options in clinical practice. That journey has become more complex. Medical education has never been so abundant \u2014 or so competitive. The problem […]<\/p>\n","protected":false},"author":5,"featured_media":1249,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[80,79],"tags":[169,167,168,164,108,71,166,165,69,127],"class_list":["post-1244","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma-medical-marketing","category-scientific-communication","tag-big-pharma-en","tag-continuing-medical-education","tag-medical-affairs-en","tag-medical-education","tag-omnichannel-pharma","tag-pharmaceutical-marketing","tag-physician-journey","tag-prescribing-behavior","tag-scientific-communication","tag-scientific-content"],"acf":[],"yoast_head":"\n1. Streaming: When Science Must Fit into the Physician\u2019s Routine<\/strong><\/h2>\n
\n
\n
2. Scrolling: Discovery Happens Before Search<\/strong><\/h2>\n
\n
3. Search: When Clinical Intent Becomes Explicit<\/strong><\/h2>\n
\n
\n
4. Selection (\u201cShopping\u201d): In Pharma, the Right Lens Is Selection and Adoption \u2014 Ultimately, Prescribing<\/strong><\/h2>\n
\n
\n
\n
\n
\n
\n
\n
\n
References:<\/h3>\n
\n